May 22, 2025 - 06:19
In a significant strategic shift, one of the largest medical technology companies is set to spin off its diabetes division within the next 18 months. This move is expected to allow the new entity to focus more intently on the growing diabetes market. Que Dallara, who currently serves as the president of Medtronic’s diabetes business, has been named the CEO of the forthcoming company, indicating a commitment to continuity and expertise in leadership.
The decision to separate the diabetes business is anticipated to enhance operational efficiency and drive innovation, particularly as the demand for diabetes management solutions continues to rise. With an increasing number of individuals diagnosed with diabetes worldwide, the new company will likely aim to leverage Medtronic's existing technologies while also investing in new developments.
This spin-off reflects broader trends in the healthcare industry, where specialized companies often outperform larger conglomerates by honing in on specific markets. Stakeholders are eager to see how this transition will unfold and what new advancements may emerge in diabetes care.
